文献速递甲状腺疾病

初始治疗选择对低危甲状腺微小乳头状癌患者2年生活质量的影响

Effect of Initial Treatment Choice on 2-year Quality of Life in Patients with Low-risk Papillary Thyroid Microcarcinoma.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该多中心前瞻性队列研究分析1055例低危甲状腺微小乳头状癌(PTMC)患者,中位随访24.4个月,比较主动监测(AS)与立即手术对2年生活质量(QoL)的影响。校正年龄、性别、基线肿瘤大小和基线QoL评分后,2年QoL由好到差依次为AS组、腺叶/峡部切除术组、全甲状腺切除术组。研究提示QoL是选择低危PTMC初始治疗的重要考量,AS可作为主要治疗选择。

要点

  • 校正混杂因素后,低危PTMC患者2年QoL由好到差依次为AS、腺叶/峡部切除、全甲状腺切除。
  • 研究共分析1055例受试者的2652份QoL问卷,中位随访24.4个月。
  • 随访中因疾病进展由AS转为手术者的QoL优于无进展而转手术者。

核心结论

  • QoL是低危PTMC初始治疗选择中的主要问题,研究提示可将AS作为首选治疗。

研究设计与样本

  • 正在进行的多中心前瞻性PTMC主动监测队列研究,分析1055例受试者的2652份QoL问卷,中位随访24.4个月。
  • 采用广义估计方程按治疗方式评估低危PTMC患者的QoL。

主要发现

  • 817例完成基线QoL问卷者中,校正年龄、性别、基线肿瘤大小和基线QoL评分后,2年QoL由好到差依次为AS组(n=500)、腺叶/峡部切除术组(n=238)、全甲状腺切除术组(n=79)。
  • 101例随访期间由AS转为手术者中,因疾病进展转手术的35例QoL优于无疾病进展而转手术的66例。

临床怎么用

  • 对低危PTMC患者,可将QoL纳入初始治疗决策,并考虑将AS作为主要治疗选择。
  • 选择立即手术时应告知不同术式对2年QoL的影响顺序。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The long-term quality of life (QoL) in patients with low-risk papillary thyroid microcarcinoma (PTMC) underwent active surveillance (AS) and immediate surgery is unclear. OBJECTIVE: The aim of this study was to investigate the effect of initial treatment choice on 2-year QoL in patients with low-risk PTMC. DESIGN, SETTING, AND PARTICIPANTS: We analyzed 2652 QoL surveys from 1055 subjects enrolled in ongoing multicenter prospective cohort study on active surveillance of PTMC, in which the median follow-up duration was 24.4 months. MAJOR OUTCOME MEASURE: We evaluated QoL of patients with low-risk PTMC according to their treatment modality using generalized estimating equation. RESULTS: Six hundred and seventy-four subjects (male = 161; mean age = 48.8 ± 11.9 years) with low-risk PTMC chose AS while 381 subjects (male = 75; mean age = 45.7 ± 10.4 years) chose immediate surgery, including lobectomy/isthmusectomy (L/I) and total thyroidectomy (TT). Among the 817 subjects who completed baseline QoL surveys, 2-year QoL was good in order of AS (n = 500), L/I (n = 238), and TT (n = 79) groups after adjustment for age, sex, baseline tumor size, and baseline QoL scores. Among the 101 subjects who changed their treatment from AS to surgery during the follow-up period, 35 subjects who changed treatment due to disease progression had better QoL than 66 subjects who had no disease progression. CONCLUSIONS: This study identified QoL as a major issue in choosing an initial treatment of low-risk PTMC and highlighted the possibility of using AS as the primary treatment.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Moon JH, Ryu CH, Cho SW, et al. Effect of Initial Treatment Choice on 2-year Quality of Life in Patients with Low-risk Papillary Thyroid Microcarcinoma. J Clin Endocrinol Metab. 2021. PMID: 33248442. doi:10.1210/clinem/dgaa889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。